| ¿µ¹® | cholinergic | ÇÑ±Û | Äݸ°(ÀÛµ¿)¼º |
|---|---|---|---|
| ¼³¸í | 1.½Å°æ¼¼Æ÷°¡ ´Ù¸¥ ½Å°æ¼¼Æ÷·Î Á¤º¸¸¦ Àü´ÞÇÒ °æ¿ì¿¡´Â ´ëºÎºÐ ÈÇй°ÁúÀ» ºÐºñÇÏ¿© ±×°ÍÀ» ¸Å°³·Î ÇÏ¿© ´Ù¸¥ ½Å°æ¿¡ Á¤º¸¸¦ Àü´ÞÇÑ´Ù. ÀÌ·± ¹°ÁúÀ» ½Å°æÀü´Þ¹°Áú¶ó°í ÇÑ´Ù. Äݸ°¼ºÀ̶õ ½Å°æÀü´Þ¹°Áú·Î acetylcholineÀ» »ç¿ëÇÏ´Â ½Å°æÀ» À̸£´Â ¸»ÀÌ´Ù. Áï ºÎ±³°¨½Å°æÀ» À̸£´Â ¸»·Î ¾²ÀδÙ. 2. Acetylcholine°ú À¯»çÇÑ ¾à¸®Àû ÀÛ¿ëÀ» ÇÏ´Â. |
||
| ¿µ¹® | cardiotonic, cardiotonic agent | ÇÑ±Û | °½ÉÁ¦ |
|---|---|---|---|
| ¼³¸í | ½ÉÀåÀÇ ¼öÃà·ÂÀ» Áõ°¨½ÃŰ´Â ¾à¹°À» ¸»ÇÑ´Ù. ±âº»ÀûÀ¸·Î ½É±Ù¼öÃà·ÂÀ» Áõ°½ÃÄÑ ½ÉÀå¹ÚÃâ·®À» Áõ°¡½ÃŰ´Â ¾à¹°ÀÌ´Ù. °½É¹è´çü, Æ÷½ºÆ÷µð¿¡½ºÆ®¶ó¾ÆÁ¦ ¾ïÁ¦Á¦, ¾Æµå·¹³¯¸° ¥â¼ö¿ëüÀÛ¿ëÁ¦, Ç÷°üÈ®ÀåÁ¦ µîÀÌ ÀÖ´Ù. ´ëÇ¥ÀûÀÎ ¿¹·Î¼´Â µð°î½Å(digoxine) µîÀÇ µðÁöÅ»¸®½º(digitalis)°¡ ÀÖ´Ù. |
||
| ¿µ¹® | alkylating agent | ÇÑ±Û | ¾ËųȾ๰ |
|---|---|---|---|
| ¼³¸í | Ç×¾ÏÁ¦ÀÇ ÀÏÁ¾. ÀÌ»óÀûÀÎ Ç×¾ÏÁ¦´Â Á¤»óÀûÀÎ ¼¼Æ÷¿¡´Â ÇØ¸¦ ÁÖÁö ¾Ê°í ´ÜÁö ¾Ï¼¼Æ÷¿¡¸¸ Ä¡¸íÀûÀÎ È¿°ú¸¦ ³ªÅ¸³»¾ß ÇÑ´Ù. ÀÌ·¸°Ô ÇÏ·Á¸é ¾Ï¼¼Æ÷¸¸ÀÇ Æ¯ÀÌÇÑ Æ¯¼ºÀ» ÀÌÇØÇÏ°í ±×°÷¿¡¸¸ ÀÛ¿ëÇÏ´Â ¾à¹°À» °³¹ßÇØ¾ß ÇÑ´Ù. ÇöÀç ´ëºÎºÐÀÇ Ç×¾ÏÁ¦´Â ¾Ï¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ¿ùµîÈ÷ Áõ½ÄÀ» »¡¸®ÇѴٴ Ư¼ºÀ» ÀÌ¿ëÇϰí ÀÖ´Ù. Áõ½ÄÀÌ ºü¸£´Ù´Â °ÍÀº ´Ù½Ã ¸»Çϸé À¯Àü Á¤º¸¸¦ °¡Áö°í ÀÖ´Â DNAÀÇ º¹Á¦°¡ ºü¸£´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ¸¸¾à DNAÀÇ º¹Á¦¸¦ ¹æÇØÇÑ´Ù¸é Áõ½ÄÀÌ ¾ÆÁÖ ºü¸¥ ¾Ï¼¼Æ÷¿¡°Ô´Â Ä¡¸íÀûÀÌÁö¸¸ ¿µ¿øÈ÷ Áõ½ÄÀ» ÇÏÁö ¾Ê´Â DNAÀÇ º¹Á¦°¡ °ÅÀÇ ÇÊ¿ä¾ø´Â)½Å°æ¼¼Æ÷³ª Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿¡ ºñÇØ¼ ¾ÆÁÖ ´À¸° Á¤»ó¼¼Æ÷¿¡´Â °ÅÀÇ ¿µÇâÀ» ÁÖÁö ¸øÇÑ´Ù. ÇÏÁö¸¸ ½Åü¿¡¼µµ Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿Í ºñ½ÁÇÑ ¼öÁØÀ¸·Î ÀϾ´Â Á¤»óÀûÀÎ ¼¼Æ÷°¡ Àִµ¥ ±×°ÍÀº ¸Ó¸®Ä«¶ôÀ» ¸¸µå´Â ¸ð³¶¼¼Æ÷¿Í ¼ÒȰüÀÇ Á¡¸·À» ÀÌ·ç´Â ¼¼Æ÷¿Í Ç÷¾×ÀÇ ¼¼Æ÷¸¦ ¸¸µå´Â °ñ¼ö ¼¼Æ÷ÀÌ´Ù. ±×·¯¹Ç·Î Ç×¾ÏÁ¦¸¦ »ç¿ëÇÒ °æ¿ì ¾Ï¼¼Æ÷¿Í ¸¶Âù°¡Áö·Î ÀÌµé ¼¼Æ÷µµ ÇÔ²² Ä¡¸íÀûÀÎ ¿µÇâÀ» ÀÔÀ» °ÍÀº ´ç¿¬ÇÏ´Ù(±×·¡¼ Ç×¾ÏÁ¦ Ä¡·á½Ã¿£ ¸Ó¸®°¡ ºüÁö°í ¼ÒȺҷ®ÀÌ Àß ¿Â´Ù). ¾ËĮȾ๰ÀÇ °æ¿ì¿¡´Â DNA¿Í Á÷Á¢ °áÇÕÀ» ÇÏ¿© DNAÀÇ º¹Á¦¸¦ ¾ïÁ¦ÇÔÀ¸·Î½á Ç×¾ÏÁ¦ÀÇ ¿ªÇÒÀ» ¼öÇàÇÑ´Ù. |
||
| ¿µ¹® | anti-inflammatory agent | ÇÑ±Û | Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à |
|---|---|---|---|
| ¼³¸í | ±¹¼Ò¿¡ ÀÛ¿ëÇÏ¿© ¿°ÁõÀ» Ä¡·áÇÏ°í ¹æÁöÇÏ´Â ¾à. ¿°ÁõÀ» °¡¶ó¾ÉÈ÷´Â ¾àÀ» ¸»ÇÑ´Ù. Á¶Á÷À» ±äÃà-Ä¡¹ÐÇÏ°Ô ÇÏ¿© Àå¾×°ú Á¡¾×ÀÇ ºÐºñ¸¦ ÁÙÀ̰í, Ç¥¸é¿¡ ÀÖ´Â ÀÛÀº Ç÷°ü¿¡ ºóÇ÷À» ÀÏÀ¸ÄÑ ÃæÇ÷µÇ´Â °ÍÀ» ¹æÁöÇÔÀ¸·Î½á ¿°ÁõÀû º´º¯À» Á¦°ÅÇÏ¿© ¸ðµç Áõ¼¼¸¦ ¾ø¾Ø´Ù. ´ëºÎºÐÀÇ ¼ö·ÅÁ¦-¿ÏÈÁ¦-Áø¾çÁ¦°¡ ÀÌ¿¡ ¼ÓÇÑ´Ù. Áß¿äÇÑ ¼ººÐÀ¸·Î´Â ¾Ë·ç¹Ì´½-ºñ½º¹«Æ®-¾Æ¿¬-³³ÈÇÕ¹°(º´¹Ý-Æä¸£¸¶Åç-¾Æ¿¬È-¿¬´ç µî) µîÀÌ ÀÖ´Ù. ÀÛ¿ë¿¡ µû¶ó Ç׿°ÁõÁøÅëÁ¦¿Í Ç׿°ÁõÈ¿¼ÒÁ¦·Î ³ª´¶´Ù. |
||
| NMB | neuromedin B; neuromuscular blockade; neuromuscular blocking; neuromuscular blocker/blocking [drug, ... |
|---|---|
| SBF | serologic-blocking factor; specific blocking factor; splanchnic blood flow |
| GBA | ganglionic blocking agent; gingivobuccoaxial |
| NMBA | neuromuscular blocking agent |
| SMCA | smooth muscle contracting agent; suckling mouse cataract agent |
| NMBA | Neuromuscular blocking agent |
|---|---|
| CBF | Cholinergic basal forebrain |
| HCNP | Hippocampal cholinergic neurostimulating peptide |
| mAChR | Muscarinic cholinergic receptors |
| NANC | Non-adrenergic non-cholinergic |
| cholinergic agent | An agent that mimics the action of the parasympathetic nervous system (e.g., methacholine). (05 Mar 2000) |
|---|---|
| cholinergic parasympathomimetic agent | <pharmacology> A chemical substance that causes the release of choline (acetylcholine) from parasympathetic nerve endings. (15 Jan 1998) |
| adrenergic blocking agent | A compound that selectively blocks or inhibits responses to sympathetic adrenergic nerve activity (sympatholytic agent) and to epinephrine, norepinephrine, and other adrenergic amines (adrenolytic agent); two distinct classes exist, alpha-and beta-adrenergic receptor blocking agent's. (05 Mar 2000) |
| adrenergic neuronal blocking agent | A drug that prevents the release of norepinephrine from sympathetic nerve terminals; it does not inhibit the responses of the adrenergic receptors to circulating epinephrine, norepinephrine, and other adrenergic amines. (05 Mar 2000) |
| alpha-adrenergic blocking agent | An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension. Synonym: alpha-blocker. (05 Mar 2000) |
| beta-adrenergic blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| blocking agent | A class of drugs that inhibit (block) a biologic activity or process, such as axonal conduction or transmission, or ions across a cell membrane; frequently called "blockers." (05 Mar 2000) |
| ganglionic blocking agent | An agent that impairs the passage of impulses in autonomic ganglia. (05 Mar 2000) |
| slow channel-blocking agent | calcium channel-blocking agent |
| neuromuscular blocking agent | A group of drugs that prevent motor nerve endings from exciting skeletal muscle. They act either by competing for the neurotransmitter, acetylcholine, (like D-tubocurarine, mivacurium and pancuronium), or by first stimulating the postjunctional muscle membrane and subsequently desensitizing the muscle endplates to the acetylcholine (like succinylcholine or decamethonium); used in surgery to produce paralysis and facilitate manipulation of muscles. (05 Mar 2000) |
| nondepolarising neuromuscular blocking agent | A compound that paralyzes skeletal muscle primarily by inhibiting transmission of nerve impulses at the neuromuscular junction rather than by affecting the membrane potention of motor endplate or muscle fibres. (05 Mar 2000) |
| receptors, cholinergic | Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behaviour of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology. (12 Dec 1998) |
| cholinergic | <pharmacology> Resembling acetylcholine in pharmacological action, stimulated by or releasing acetylcholine or a related compound. (15 Jan 1998) |
| cholinergic agents | Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of acetylcholine, and drugs that affect the survival of cholinergic neurons. The term cholinergic agents is sometimes still used in the narrower sense of muscarinic agonist, although most modern texts discourage that usage. (12 Dec 1998) |
| cholinergic blocking agent |
Anticholinergic (2)..
Ãâó:
|
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|